Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found throughout the extracellular matrix, prized for its extraordinary capacity to bind water — up to roughly a thousand times its own weight under ideal conditions. In its native form, however, HA is degraded by hyaluronidase enzymes within roughly 24 to 48 hours in tissue, which makes it useless as an injectable filler without modification. Crosslinking technology exists to solve exactly this problem: extending HA's residence time in tissue while preserving, as much as possible, its biocompatibility and hydrophilic behaviour.
What crosslinking actually does
Crosslinking introduces covalent bonds between adjacent HA polymer chains, using a crosslinking agent — most commonly 1,4-butanediol diglycidyl ether (BDDE) — to link hydroxyl groups on separate chains. The result is a three-dimensional gel network rather than a solution of free-floating polymer strands. This network resists both enzymatic degradation and mechanical washout far longer than uncrosslinked HA, which is what gives modern fillers their multi-month to multi-year longevity.
Crosslinking degree, particle size, and rheology
Two variables largely determine a filler's clinical behaviour: the degree of crosslinking (the proportion of HA chains bonded, and how densely) and whether the resulting gel is processed into discrete particles (particulate/cohesive-particulate gels) or left as a continuous monophasic network. These variables in turn determine the two rheological properties clinicians actually feel and rely on at the point of injection:
- G′ (elastic modulus) — the gel's resistance to deformation, correlating clinically with lifting capacity and structural support.
- Cohesivity — how strongly the gel holds together as a mass, influencing spread, integration with surrounding tissue, and resistance to migration.
A high-G′, low-cohesivity gel behaves very differently under the needle from a low-G′, high-cohesivity gel, even at identical HA concentration — which is why product selection by rheological profile, not brand name alone, is the more defensible clinical practice, and the more rigorous one to teach.
Why crosslinking degree matters for reversibility
Hyaluronidase, the enzyme used to dissolve unwanted or malpositioned filler, acts more slowly on heavily crosslinked gels than on lightly crosslinked or native HA. This is a double-edged consideration in practice: greater crosslinking generally buys duration, but at some cost to how quickly an adverse placement can be corrected. This tradeoff is central to why filler selection in high-risk anatomical zones (e.g. the nose, glabella) tends to favour products with a demonstrated faster, more predictable hyaluronidase response, even at some cost to longevity.
Residual BDDE and biocompatibility
Regulatory testing (and the MDR clinical evidence requirements discussed in Module 1) requires manufacturers to demonstrate that unreacted, free BDDE remaining in the finished gel is reduced to trace levels considered non-biologically significant. This is one of the manufacturing quality variables that genuinely differentiates reputable filler brands from unregulated or grey-market products, and is a useful anchor point for teaching students why sourcing and CE documentation matter beyond regulatory box-ticking.